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Neonatal eposure to diethyistilbestrol (DES) can alter the structure ofthe testicular excurrent
ducts in rats. We characterized these changes according to dose and time posttreatment and
established whether potent estrogens (ethinyI estra , environmental estrogens (genistein,
oct lbisphenol A, paraben) and tamoxifenainuce h c Ras were
tered thesecompouinds neonatallyand assesed at seerl time points during (day 10, orday 18
for some treatments) and after (cays 18, 25, 35, and 75) te treament period to detect any
changes in testi weight, distension ofthe rete test and efferent ducts, epitelial cell height in
the efferent ducts, and immunoexpression of the water channel aquaporin-1 (AQP-1).
Treatment with DES (10, 1, or 0.1 pg/injection; equivalent to 0.37, 0.037, or 0.0037
mg/kg/day, ptiv) induced dose-d ndent in i and all p
These efft were most pronou at days 18 and 25 and appeiaed to lessen with time,
although somepersisted into adulthood. Neonatal treatment withetbinyl estradiol (10 pg/injec-
tion; equivlent to 0.37 mg/lk/day) caused changes broadly similar to those induced by 10 pg
DES. Administration oftam ifen (2mg/ig/day) caused chansat 18 daysthat were similar to
those induced by 1 pg DES. Treatmentwith genistein (4 mg/kg/day), octylphenol (2 mg/injec-
tion; equivalent to 150 mg/kg/day), or bisphenol A (0.5 mg/injection; equivalent to 37
mg/kg/dry) caused minor but s #0.05) de in epithell c heightoftheeffer
ent ducts atdays 18 andlor 25. In animals that were fllo through to35 days and/oradut-
hood, these changes were no longer obvious; other parameters were either unaffcted or were
affected only marginally and transiently. Administration ofparabens (2 mg/kg/day) had no
detectable efect on anyparameter atday 18. To establishwhether these effect ofestrogens were
direct or indirect (i.e., resuling from reducedfollicle-stimulating hormone/lutenixing hormone
secretion), the above end points were assessed in anaimls in which gondtopin secretion was
suppressedneonatally by adminirtion ofa g in-reeasing h antagonist. This
treatment perenty reduced tetis weight, but did not affect any of the other end points,
apart from a minor transient reduction in efferent duct epithelial cell height at 18 days. This
study suggests that structural and functional (expression ofAQP-1) dvlopment ofthe excur-
rent ducts is susceptible to impairment by neonatl estrogen exposure, probably as a conse-
quence ofdirect effects. The m nude and duration ofadverse changes induced by treatment
with a range of estrogenic compunds was broa cpable to teir h estrogenic potencies
reported from in vito assays. Key work aquaporin-1, bisphenol A, diethyislbestrol, efferent
ducts, ethinyl estradiol, genistein, octylphenol, rete tetis, tmifen. Environ Healtb Perspect
107:397-405 (1999). [Online 6April 1999]
bthp://lehpnetl.niehs.nis.gou/docs/19991107p397-405fubcerlabtbrtm1
Estrogen, the classical female hormone, is
nowbeinginvestigated to determine its func-
tion in male fertility. This has become an
increasingly important issue over the past 5
years because datasuggest that there has been
a progressive increase in disorders of male
reproductive development and there is con-
cern as to whether compounds in the envi-
ronment could have contributed to these
adverse changes. Studies have suggested that
human sperm counts have declined in some
countries according to later year of birth
(1-4) and that the incidence of testicular
cancer and some congenital abnormalities
(hypospadias and cryptorchidism) have
increased in many countries over the same
time period (5-9). These changes coincide
with major changes in lifestyle and with the
mass production of synthetic chemicals
involved in the production ofindustrial and
domestic commodities (such as pesticides
and plastics), some of the ingredients of
which have been shown to be weakly estro-
genic (xenoestrogens) (10-16). As perinatal
exposure of male animals and humans to
synthetic estrogens can induce similar
adverse changes in male reproductive health,
it has been hypothesized that inappropriate
exposure to estrogens (from inside or out-
side the body) during critical periods of
development may interfere with mecha-
nisms involved in the development of the
reproductive system and in determining
sperm numbers (17).
A major obstacle to tackling this issue
and defining whether environmental hor-
mone disruptors pose a risk to male repro-
ductive health is the lack of relevant
estrogen-regulated end points within the
male reproductive system. Recent studies,
however, have highlighted the regions ofthe
male reproductive tract that appear to be
important sites ofestrogen action. One such
site is the efferent ducts thatjoin the testis to
the initial segment of the epididymis. The
efferent ducts comprise a simple epithelium
that is composed largely of two cell types
(ciliated and nonciliated cells), which nor-
mally display a highly columnar appearance.
Studies have shown that the efferent ducts
express both forms of the estrogen receptor
(ER-a and ER-P) (18) and that this region
is an important site for the resorption of
fluid which enters the efferent ducts along
with spermatozoa from the rete testis. This
fluid resorption is impaired in transgenic
animals lacking a functional ERa receptor,
suggesting that estrogens may play a role in
fluid resorption (19).
The lack of relevant estrogen-regulated
end points within the male reproductive
tract prompted us to assess estrogen exposure
using parameters that we have previously
identified as being altered after neonatal
administration of a high dose (10 pg/injec-
tion) ofdiethylstilbestrol (DES). Exposure to
DES induces gross morphological alterations
to the rete testis and efferent ducts (20). The
rete testis becomes grossly enlarged and dis-
tended with the distension persisting
throughout the efferent ducts. The epithelial
cells of the efferent ducts decrease in height
coincident with reduced expression of the
water channel protein aquaporin-1 (AQP-1),
which is normally located on the brush bor-
der ofnonciliated cells. In the present study,
we aimed to assess the effects of neonatal
exposure to estrogens and estrogenic com-
pounds in a more definitive manner by
examining both dose- and time-dependent
responses to neonatal administration ofvari-
ous doses of DES and comparing these to
neonatal treatmentwith ethinyl estradiol and
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the estrogen receptor antagonist/agonist
tamoxifen. To determine whether these are
reliable end points with which to assess
exposure to environmental estrogens, we
examined the excurrent ducts of animals
treated neonatally with some weakly estro-
genic chemicals (octylphenol, bisphenol A,
parabens) at concentrations approaching
their maximum solubility in oil, and the
phytoestrogen genistein at levels equivalent
to total phytoestrogen intake by human
infants consuming soy formula. For most of
these chemicals, attention was focused on
postnatal day 18, as this was the age when
the most pronounced effects were observed
in animals treated neonatallywith DES.
Materials and Methods
Animab. Wistar rats bred in our own ani-
mal facility were maintained under standard
conditions. Neonatal rats were subjected to
subcutaneous injection with one of the
treatments described below. All compounds
other than genistein and gonadotropin-
releasing hormone antagonist (GnRHa)
were administered in corn oil to provide a
subcutaneous depot that would ensure con-
tinuous exposure to the test compound
throughout the day. Some treatments were
administered on a kilogram per day basis,
whereas others were administered in a con-
stant dose/volume per injection. For the lat-
ter treatments, an approximate intake in
milligrams per kilograms per day has been
indicated based on the average weight and
age for animals during the treatment period
(i.e., 2-12 days ofage). However, this value
is onlyan average; also, in neonates 2-6 days
of age, not all of the oil (and presumably,
test compound) is absorbed from the injec-
tion site between consecutive injections.
Treatments. DES (Sigma, Poole, Dorset,
UK) was administered ateither 10, 1, or 0.1
pg in 20 p1 corn oil on postnatal days 2, 4,
6, 8, 10, and 12 (day ofbirth = day 1), giv-
ing doses ofapproximately 0.37, 0.037, and
0.0037 mglkg/day, respectively. GnRHa
(Antarelix; Europeptides. Argenteuil,
France), 10 mg/kg in 20 pl 5% mannitol,
was administered on postnatal days 2 and 5.
Ethinyl estradiol (Sigma) was given at 10 pg
in 20 p1 corn oil on postnatal days 2, 4, 6, 8,
10, and 12, equivalent to approximately
0.37 mg/kg/day. Bisphenol A (Aldrich
Chemicals Limited, Dorset, UK) was
administered at 0.5 mg in 20 p1 corn oil on
days 2-12 inclusive, equivalent to 37
mg/kg/day. Octylphenol (Aldrich), 2 mg in
20 pl corn oil, was given on days 2-12
inclusive, equivalent to 150 mg/kg. Butyl-
parabens (a gift from John Ashby, Zeneca
CTL, Macclesfield, Cheshire, UK) was
injected at -2 mg/kg/day in 2 ml/kg corn oil
on days 2-18 inclusive; animals that were
sampled on day 18 were killed 4 hr after
theirdailyinjection.
Genistein (Sigma) was administered at
-4 mg/kg/day in 2 ml/kg vehicle [phos-
phate-buffered saline (PBS) + 2.5 mg/ml
gelatin]. Genistein was first dissolved in
0.4M KOH and diluted 1:20 with PBS to
give a dosing concentration of 800 pg/ml.
The mothers ofrats treated neonatallywith
genistein and their respective controls
(treated with the appropriate vehicle) were
fed on a casein-based, soy-free diet (B.S. &
S., Edinburgh, Scotland). Rats killed on
days 10 and 18, while they were still on
treatment, were killed 4 hr after their daily
injection. Tamoxifen (Sigma) was adminis-
tered at -2 mg/kg in 20 p1 corn oil on days
2-16 indusive. Controls for all ofthe treat-
ments were injected with the equivalent
volume ofvehicle.
The selection of doses for the above
compounds was based on the following con-
siderations. The highest DES dose was
based on our previous studies (20,21), and
the single dose ofethinyl estradiol testedwas
selected to be equivalent to this DES dose.
The dose and treatment regimen for
GnRHa was based on previous studies
(21,22) that showed complete suppression
offollicle-stimulating hormone (FSH) levels
through to day 18. The doses ofbisphenol
A and octylphenol were based on maximum
solubility ofthe compounds in oil, and the
dose of butyl-parabens was based on recent
studies of its effects in vivo on uterine
weight in the rat (10). The dose ofgenistein
was based on figures calculated by Setchell
et al. (23) that show the total isoflavanoid
intake by human infants fed on a 100% soy
formulamilkdiet.
Tissuefixation. Animals from control,
bisphenol A-, and DES- (10 pg) treated
groups were killed at 10, 18, 25, 35, and 75
days of age. Rats treated neonatally with
GnRHa or lower doses of DES (1 or 0.1
pg) were sampled at days 18, 25, 35, and
75. Genistein-treated rats were killed at 10,
18, 25, and 75 days of age. Rats treated
with ethinyl estradiol were sampled at 18,
25, and 75 days ofage, whereas rats admin-
istered butyl-parabens or tamoxifen and
their respective controls were all killed at
just one time-point, 18 daysofage.
Animals 10-25 days ofage were killed
by inhalation of carbon dioxide or
halothane and subsequent cervical disloca-
tion. In animals up to 25 days of age, the
testes and epididymides were removed
together and immersion fixed in Bouin's
fixative for 5.5 hr at room temperature
before being transferred into 70% ethanol.
After 35 days ofage, rats were anesthetized
with halothane and perfusion fixed via the
thoracic aorta with 0.9% saline containing
0.01% heparin until the testicular blood
vessels deared; tissues were then fixed with
Bouin's fixative for 30 min, as described
previously (24). Each testis and epididymis
were then dissected apart to leave the effer-
ent ducts attached to the testis. After being
postfixed for a further 5.5 hr in Bouin's fix-
ative, these tissues were then transferred
into 70% ethanol. One testis from each
animal was weighed. In animals under 35
days ofage, the fresh weight was recorded,
whereas weights in animals 35 or 75 days
of age were recorded after perfusion fixa-
tion. Fixation in Bouins fixative causes neg-
ligible tissue shrinkage, and data for fixed
and unfixed testis weights from similarly
treated animals do not differ significantly.
Therefore, data for unfixed and fixed testis
weights can be compared direcdy.
Tissue processing. Fixed tissue was
processed for 17.5 hr in an automated Leica
Tp-1050 processor (Leica UK Limited,
Milton Keynes, UK) and embedded in
paraffin wax. Sections were cut at 5 pm and
floated onto coated slides (2% 3-amino-
propyltriethoxy-saline; Sigma) and dried at
50°C overnight before immunocytochem-
istrywas performed.
Immunocytochemistry. Immunolocaliz-
ation ofAQP-1 was determined using a
polyclonal antibody raised to human ery-
throcyte AQP-1, the validation ofwhich is
described elsewhere (20,25). The antibody
and preimmune serum were used at a dilu-
tion of 1:500. Slide-mounted sections
were dewaxed in Histoclear (National
Diagnostics, Fleet Business Park, Hull,
UK), rehydrated through a graded series of
ethanol, and washed in distilled water. To
block endogenous peroxidase activity, the
sections were pretreated with 3% hydrogen
peroxide in methanol. Nonspecific binding
sites were blocked by incubating the sec-
tions in normal swine serum (NSS) diluted
1:5 in Tris-buffered saline (TBS, pH 7.4,
containing 50mM Tris-HCI, 150 mM
NaCI). The immune and preimmune sera
were diluted in the NSS block and 100 pl
was added to each slide, which was then
coverslipped and incubated overnight in a
light-proofbox at 40C. After removing the
coverslips, the slides were washed in TBS
(two times at 5 min each) and then incu-
bated with a linking antibody, biotinylated
swine-antirabbit serum (DAKO Ltd.,
Cambridge, UK; diluted 1:500 in NSS) for
30 min. After two washes in TBS,
avidin-biotin conjugated horseradish per-
oxidase (DAKO) was applied to the slides
for 30 min. The slides were given two final
rinses in TBS before the addition of a
diaminobenzidine (DAB)-based chro-
mogen, which left a brown precipitate at
the sites ofantibody localization. The slides
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were developed until the color on control
sections reached the required intensity
before the reaction was stopped by immers-
ing the slides in distilled water. The slides
were then counterstained with hema-
toxylin, dehydrated by immersion in a
graded series of ethanol, and cleared in
xylene. A coverslip was fixed over the sec-
tions using Pertex mounting medium (Cell
Path, Hemel Hempstead, UK).
Evaluation ofimmunostaining. Slides
were examined and photographed using
an Olympus Provis microscope (Olympus
Optical, London, UK) fitted with a
Kodak DCS420 camera (Eastman Kodak,
Rochester, NY). Captured images were
stored on an 8100 PowerPC computer
(Apple MacIntosh, Apple Computer,
Cupertino, CA) and compiled using
Photoshop 3.0 (Adobe Systems Inc.,
Mountain View, CA) before being printed
using a Kodak XLS 8600 PS printer
(Eastman Kodak). To enable accurate com-
parison ofimmunostaining between treated
and control animals, immunocytochemistry
was performed with sections from control
and treated animals side by side on the
same slide; thus, each control section acted
as an internal control to compare the inten-
sityofimmunostaining. Tissue from at least
three animals at each age and treatment
were evaluated on at least three occasions to
ensure the reproducibility ofthe results.
Rete testisandefferentductmorphology.
Tissue sections were prepared as described
above and were stained with hematoxylin
and eosin. Sections were then viewed under
a light microscope to examine the morphol-
ogy of the efferent ducts and rete testis.
Slides were used for analysis of epithelial
cell height in the efferent ducts or, where a
good cross section ofthe rete testis had been
obtained, the slide was photographed using
the system described above. To ensure con-
sistency regarding the cross-section of the
rete testis that was photographed, slides
were chosen if the region of the rete testis
which joins the efferent ducts could be
viewed in the plane ofsection.
Efferent duct epithelial cell height. Our
previous study (20) demonstrated that
neonatal treatment with 10 pg DES altered
the shape and height of epithelial cells in
the efferent ducts. To evaluate whether sim-
ilar changes were induced by the present
treatments, cross-sections of efferent ducts
were evaluated using image analysis from
3-20 rats from the control and treated
cohorts at all time points collected. The
height of the efferent duct epithelium was
measured using an Olympus BH2 micro-
scope fitted with a 40x plan achromat
objective and a 3.3x phototube (Olympus
Optical). The image was captured using a
Sony XC77CE video camera (Sony, Tokyo,
Japan) linked to a personal computer with
frame grabber and image pro image analyses
software (Media Cybernetics, Silver Spring,
MD). Using the length tool, we measured
the height ofthe epithelium at right angles
from the base of the cell adjacent to the
basement membrane to the luminal surface
of the cell. After measuring the length, the
angle of the line was measured to ensure
that it was at 90 degrees. For each animal,
we measured at least 50 cells, with sampling
from a number of different ducts, and cal-
culated the mean value.
Statistics. We compared testis weights
and efferent duct epithelial cell height for
control and treated groups at each age
point using analysis ofvariance; where sig-
nificant differences between groups were
indicated, subgroup comparisons utilized
the same test, but the overall variance
served as the measure oferror.
Results
Testis weight after neonatal estrogen expo-
sure. Testis weights were compared between
control and treated cohorts at 18, 25, 35,
and 75 days ofage. Testicular size has previ-
ously been shown to be decreased after post-
natal exposure to estrogenic compounds
(26) and usually provides a gross indication
of the total number of cells within each
testis. Testis weights were significantly
reduced at all ages after treatment with
GnRHa, ethinyl estradiol, and all three
doses of DES (Fig. 1). As the soy-free con-
trol data did not differ significantly from
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control animals in any parameter assessed at
day 18 (except testis weight), for simplicity,
at all other ages assessed, the data from soy-
free control animals were pooled with "nor-
mal" control data.
Day 18. At day 18, neonatal exposure to
high doses ofpotent estrogens (DES 10 pg,
DES 1 pg, ethinyl estradiol 10 pg) all caused
highly significant reductions in testis weight.
A similar reduction was induced by adminis-
tration of GnRH antagonist or tamoxifen
(Fig. 1). Animals treated with weakly estro-
genic compounds (bisphenol A and
parabens) showed no alteration in testis
weights when compared to control animals,
but animals treatedneonatallywith octylphe-
nol displayed a significant increase in testis
weight. Rats that had been treated with
genistein and their controls were born to
mothers which had been fed a soy-free diet
andwere maintained on this diet postnatally.
The testis weights of genistein-treated and
soy-freecontrols did notdiffersignificandy.
Day 25. The testis weights of animals
killed on day 25 (Fig. 1) showed a similar
pattern to those described for day 18.
Animals treated neonatally with high doses
of estrogen (DES 10, 1, 0.1 pg; ethinyl
estradiol) demonstrated highly significant
reductions in testis weights similar to the
reduction obtained after administration of
GnRHa (Fig. 1). Administration of the
weakly estrogenic compounds (octylphe-
nol, bisphenol A, and gensitein) had no
detectable impact on testis weight.
Days 35 and 75. Testis weights at day
35 and in adults demonstrated similar
_ S Control
M GnR a (10 mg/kg)
X~~~~~~~~~~DES..g g) Ethinylestradiol (0.g
MTamoxifen (-2mg/g
MOctylphenol (2mg
M BisphenolA(0.5mg
M Parabens(2mglkg Soy-free control
M Genistein (4mgkg)
Treatment **
Treatment Treatnment
Figure 1. Effect of neonatal treatmentwith a gonadotropin-releasing hormone antagonist (GnRHa) or vari-
ous estrogenic compounds on testis weights of animals from 18 to 75 days of age. DES, diethylstilbestrol.
The data shown are means ± standard deviations for 3-20 animals/group. The genistein-treated animals
were compared with the soy-free control group on day 18.
**p<4.01;#p<0.001 in comparison withthe respective control group.
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Table 1. Subjective comparison of changes in aquaporin-1 (AQP-1) immunoexpression and rete testis distension in control and treated animals at 10, 18, 25, 35,
and 75 days of age
Day 10 Day 18 Day 25 Day 35 Day 75
Treatment AQP-1 n Rete n AGP-1 n Rete n AQP-1 n Rete n AQP-1 n Rete n AQP-1 n Rete n
Control +++ 5 P 3 +++ ll P 5 +++ 20 P 8 +++ 6 P 6 +++ 6 P 6
Soy-free control +++ 13 P 3
GnRHa +++ 12 P 4 +++ 8 P 6 +++ 3 P 3 +++ 5 P 4
DES (10 pg) + 4 MG 3 + 14 MG 9 + 9 MG 3 ++ 6 FE 4 +++ 6 FE 4
DES(lpg) - + 10 MG 5 +± 4 P 3 +++ 5 FE 4 +++ 4 P 3
DES(0.1pg - - - + 10 MG 4 +± 4 P 4 +++ 4 P 3 +++ 4 P 3
Ethinyl estradiol (10 pg) - + 4 MG 4 + 7 P 5 FE 3
Genistein (4 mg/kg) +++ 5 P 4 +++ 14 P 4 +++ 7 P 3 +++ 5 P 4
Bisphenol A (0.5 mg) +++ 4 P 4 +++ 6 P 6 +++ 5 P 4 +++ 7 P 3 +++ 3 P 3
Octylphenol (2 mg) ++ 8 P 4 ++ 6 P 3
Parabens (2 mg/kg) - ++ 6 P 3
Tamoxifen (2mg/kg) ++ 5
Abbreviations: DES, diethylstilbestrol; GnRHa, gonadotropin-releasing hormone antagonist; +++, control level of AQP-1 immunostaining; ++, reduced level of immunostaining; +, major
reduction in the level of immunostaining; ±, few cells with immunostaining; P, patent rete testis; FE, signs of fluid retention and enlargement of rete testis; MG, major fluid retention and
gross enlargement of rete testis.
Figure 2. Effect of neonatal administration of a gonadotropin-releasing hormone antagonist (GnRHa) or
various estrogenic compounds (see Table 1 for doses) on immunoexpression of aquaporin-1 (AQP-l) in
the efferent ducts of rats at postnatal day 18. DES, diethylstilbestrol. The genistein-treated animal is
most appropriately compared with the soy-free (SF) control. Bar in the control panel = 50 pm. Asterisks
indicate sections in which there are distended lumens in the efferent ducts.
changes as the earlier ages. Highly signifi-
cant decreases in testis weights were still evi-
dent after neonatal treatment with all doses
ofDES; the maximal reduction (induced by
10 pg DES) was similar to that produced by
neonatal administration ofGnRHa (Fig. 1).
Neonatal administration ofbisphenol A did
not cause any reduction in adult testis
weight, although at 35 days of age (Fig. 1)
there was a slight but significant decrease in
testis weight in this group. This may have
been a chance observation or it could indi-
cate that these animals had slightly delayed
puberty. Animals treated neonatally with
genistein had marginally but significantly
larger testes in adulthood (Fig. 1).
Immunoexpression ofAQP-J and effer-
ent duct morphology. Immunoexpression of
AQP-1 was performed on a cohort of ani-
mals from all treatment groups at all ages.
Due to the volume of data generated, the
results were tabulated and photomicrographs
were compiled for all treatment groups at
postnatal day 18. This time point was select-
ed because it was the age when the most pro-
nounced changes occurred after DES admin-
istration; thus, we considered that milder
treatment regimes would be most likely to
induce detectable changes at this time point.
Day 10. Data for AQP-1 immunoex-
pression is tabulated in Table 1. At day 10
in control animals, AQP-1 formed a strong
apical band ofstaining along the brush bor-
der of the efferent duct epithelium, as is
shown for a control animal at day 18 in
Figure 2. At day 10, when animals injected
with 10 pg DES were still undergoing treat-
ment, the efferent ducts had a greatly
reduced level ofAQP-1 immunoexpression
(not shown). In the same group, the efferent
duct epithelial cell height appeared notice-
ably reduced and the efferent duct lumens
appeared distended. Treatment with weakly
estrogenic compounds (genistein or bisphe-
nol A) caused no detectable reduction in the
intensity ofAQP-1 immunoexpression or in
efferent duct morphology (not shown).
Day 18. The results ofAQP-1 immuno-
staining are described in Table 1, and repre-
sentative photomicrographs for all treatment
groups are shown in Figure 2. High power
oil immersion images are also shown for
some treatments in Figure 3 to illustrate
more clearly the alterations to the efferent
duct epithelium. At day 18 in control rats,
AQP-1 immunostaining was clearly evident
along the apical brush border ofthe efferent
duct epithelium and along the basolateral
surface ofthe epithelial cells. There was very
little immunoreactive AQP-1 along the
basal border ofthe efferent ducts. Similarly,
in animals treated with GnRHa, there was
strong, apical immunolocalization ofAQP-1
Volume 107, Number 5, May 1999 * Environmental Health Perspectives 400
ol...Articles * Estrogens and the excurrent ducts
to the efferent duct epithelium, the intensity
of immunostaining being comparable to
control levels. Epithelial cell height in
GnRHa-treated rats appeared slightly
reduced, but there was no evidence of dis-
tension of the efferent duct lumen; indeed,
lumens appeared reduced in size in compari-
son to lumens from control animals (Fig. 2).
In contrast, treatment with potent estrogens
(DES 10 jig, 1 pg, and 0.1 pg, and ethinyl
estradiol 10 pg) induced a gross and dose-
dependent reduction in the level of
immunoreactive AQP-1, such that animals
treated neonatally with 10 pg DES had
almost no detectable AQP-1 immunostain-
ing (Fig. 2, Table 1). All ofthese treatments
also caused distension of the efferent duct
lumen and an apparent reduction in height
of the epithelial cells. Neonatal treatment
with tamoxifen also caused marked changes
in the level ofAQP-1 immunoexpression,
distension of the efferent duct lumen, and
apparent reduction in epithelial cell height.
These changes were similar in magnitude to
those induced after neonatal treatment with
1-10 jig DES (Fig. 2, Table 1).
Administration ofweaklyestrogenic com-
pounds (octylphenol, bisphenol A, and
parabens) produced no gross changes in the
level ofAQP-1 immunostaining, although
there was the suggestion ofa minor but con-
sistent reduction in immunoexpression after
octylphenol treatment (Fig. 2). Theoctylphe-
nol group also appeared to have slightly, but
consistently, larger lumens in their efferent
ducts than did the controls; this was not
observed in rats treated neonatally with
bisphenol Aor parabens. All parameters mea-
sured were comparable in genistein-treated
and soy-free controls. Individual efferent
ducts were examined and photographed
under higher power magnification to high-
lightsomeofthechanges describedabove.
In controls the efferent ducts were com-
posed of a highly columnar, polarized
epithelium, with a brush border evident on
the apical membrane where AQP-1
immunolocalized. The nuclei ofthe noncil-
iated cells are in the basal region ofthe cell,
with the nuclei of ciliated cells in a more
central location. The lumen of the duct
forms an irregular shape in cross-section.
No consistent change to this appearance
was evident after neonatal treatment with
bisphenol A. In contrast, high dose estrogen
treatment (DES or ethinyl estradiol, 10 pg)
resulted in alteration of the epithelial cells
from a high columnar to a cuboidal shape
(Fig. 3). These cells appeared to lack most
of their apical cytoplasm as well as the
brush border and its associated immunoex-
pression of AQP-1. The lumens of the
efferent ducts in these animals were much
more regular and spheroidal in cross-section
Figure 3. Oil immersion, high power photomicrographs of efferent duct epithelial cell morphology and
immunoexpression of aquaporin-1 (AQP-1) in animals treated neonatally with various estrogenic com-
pounds to illustrate the coincidence of changes in AGP-1 immunoexpression, lumenal distension, and
reduction in epithelial cell height. Bar in the control panel = 500 pm. Note the heterogeneity ofthese end
points in efferentducts from animalstreated with 0.1 pg diethylstilbestrol (DES).
(as if turgid) when compared to controls.
There was also thickening of the layer of
peritubular cells that lie around the outside
of the duct. The latter was confirmed by
immunohistochemical staining of these
cells using an antibody to smooth muscle
actin (data not shown). In animals treated
with the lowest dose of DES (0.1 jig), we
observed efferent ducts that contained
epithelial cells with characteristics compa-
rable to control animals, whereas other
ducts, which were evident in the same
cross-section, displayed morphological
characteristics that were similar to those
observed after high dose DES treatment
(Fig. 3). This heterogeneity ofductal mor-
phologywas a consistent finding in animals
from this group.
Days 25, 35, and 75. The results
describing the level ofAQP-1 immunostain-
ing at 25, 35, and 75 days of age, after
neonatal estrogen treatment, are shown in
Table 1. Control animals displayed a similar
pattern and intensity of immunostaining as
shown forday 18 (Fig. 2). This was unaffect-
ed by treatment with GnRHa, similar to day
18, whereas treatment with potent estrogens
(DES or ethinyl estradiol) caused reductions
in the level ofAQP-1 immunostaining coin-
cident with alterations in the morphology of
the efferent duct epithelial cells. These
changes were still evident at day 35, but the
level of immunostaining for AQP-1 had
greatly increased in comparison with day 25,
and by adulthood, was indistinguishable
from controls. Animals treated neonatally
with weakly estrogenic compounds again
showed similar levels ofAQP-1 to those
described for day 18, with no gross change
from control; one exception was octylphe-
nol-treated animals at day 25 in which
immunoexpression may have been slightly
reducedcompared to controlanimals.
Rete testis morphology. In our initial
study using high dose (10 pg) DES, we
observed abnormal distension and over-
growth of the rete testis. In the present
report we have expanded these observations
to encompass different ages and treatments
to determine the effects on the rete testis of
a range of potent and weakly estrogenic
chemicals. Again due to the volume ofdata
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generated from this comparison, the results
have been tabulated in Table 1 and repre-
sentative photomicrographs are shown to
illustrate the results obtained for days 18
and 75, which are shown in Figures 4 and 5,
respectively.
Day 10. At day 10 in control animals
and in rats treated neonatally with weakly
estrogenic compounds (genistein and
bisphenol A), the epithelium was cuboidal-
low columnar. In contrast, after neonatal
administration of 10 pg DES, the rete testis
was grossly distended and the epithelial cells
of the rete testis had become flattened and
almost squamous in appearance (not shown).
Day 18. In control animals at day 18
(Fig. 4) the epithelium ofthe rete testis was
reduced in height in comparison to animals
at day 10, but neonatal treatment with a
GnRH antagonist appeared to delay this
flattening ofthe epithelial cells because they
still appeared cuboidal, similar to that
exhibited by controls on day 10. Treatment
with high doses of potent estrogens (DES _euo>_b2srw
.us9r _ _ s _r _ _ .,,,-,k___
Ir s I J st n n
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Figure 4. Effect of neonatal administration of a gonadotropin-releasing hormone antagonist (GnRHa) or
various estrogenic compounds on the morphology ofthe rete testis at postnatal day 18. Asterisks indicate
sections in which the rete testis is distended or overgrown. Bar in the control panel = 200 pm.
10 1.g and 1 pg and 10 pg ethinyl estradiol)
induced gross distension of the rete testis
(Fig. 4), a change that was not evident in
animals treated with 0.1 pg DES. The
degree of distension of the rete testis after
neonatal exposure to DES appeared to be
dose dependent, and the more severe dis-
tension was accompanied by deeper inva-
sion ofthe rete into the testicular parenchy-
ma. Neonatal treatment with weakly estro-
genic compounds, octylphenol, bisphenol
A, genistein, and butyl-parabens (not
shown), had no detectable effect on the
morphology ofthe rete testis (Fig. 4).
Days 25 and 35. In animals assessed at
day 25, the gross enlargement of the rete
testis was still evident in animals exposed to
10 pg DES (but not at lower doses) or
ethinyl estradiol (Table 1). Similarly, at day
35 signs offluid retention and distension of
the rete testis were only evident in animals
treated neonatally with 10 or 1 pg DES
(animals treated with ethinyl estradiol were
not assessed at this time point).
Day 75. In adulthood there was no sign
ofabnormal fluid build up or rete testis dis-
tension in control (Fig. 5) or GnRHa-treat-
ed animals (not shown). However, there
were still signs of abnormal distension in
animals treated neonatally with DES (10
pg) or ethinyl estradiol, although the severi-
ty of these effects was much reduced (Fig.
5) when compared with earlier time points.
These treatments also disrupted normal
spermatogenesis, as many seminiferous
tubules (particularly those lying underneath
the rete testis) were largely depleted ofgerm
cells or were Sertoli cell only and displayed
a4 v/
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Figure 5. Effect of the neonatal administration of various estrogenic compounds on morphology of the rete testis in adulthood (day 75). Note the presence of
germ-cell depleted seminiferous tubules in animals treated with 10 pg diethylstilbestrol (DES) or ethinyl estradiol. Asterisks indicate sections in which the rete
testis is distended. Bar in the control panel = 200 pm.
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distended lumens. There were no obvious
changes within the rete testis of animals
treated neonatally with lower doses ofDES
(1 or 0.1 pg) or bisphenolA.
Efferent duct epithelial cell height. The
photomicrographs in Figure 3 demonstrate
that neonatal estrogen treatment appeared to
alter the height of the epithelial cells of the
efferent ducts, thus, this was quantified for
the various treatment groups at each time
point. At day 10, the only time point assessed
when rats were still on treatment, there was a
significant reduction (p<0.05) inepithelial cell
height after administration of 10 pg DES
[control = 12.9 ± 1.8 pm (n = 5); DES = 8.6
± 1.0 (n = 4); mean ± standard deviation
(SD)]. There was no change in epithelial cell
height after the administration ofbisphenol A
or genistein on day 10 (data not shown). At
day 18, all of the chemicals administered
neonatally (except parabens) caused a signifi-
cant reduction in epithelial cell height (Fig.
6). Soy-free control animals had epithelial cell
heights thatwere comparable to the "normal"
control population at day 18 (Fig. 6) and at
later time points (data notshown). Treatment
with GnRHa induced a small but significant
reduction in efferent duct epithelial cell
height at day 18, but was without effect
beyond this time point. Administration ofthe
highest dose ofDES (10 pg) induced ahighly
significant reduction in epithelial cell height,
which was most severe at postnatal days 18
and 25 postnatal (Fig. 6). In this group, cell
height was still significantly reduced in com-
parison to control levels at day 35; although
a small decrease was still evident in adult-
hood, this did not reach statistical signifi-
cance. The reduction in epithelial cell height
was not as severe after the administration of
lower doses ofDES (1 and 0.1 pg); byeither
day 75 (DES 1 pg) or day 35 (DES 0.1 pg),
epithelial cell heights had recovered to con-
trol levels. Administration ofethinyl estradi-
ol induced a reduction in epithelial cell
height which was similar in magnitude to
that induced by 10 pg DES at all ages
assessed (Fig. 6). Administration of tamox-
ifen (assessed only on day 18) induced a sig-
nificant reduction in epithelial cell height
similar to that induced by 0.1-1 pg DES.
Octylphenol, bisphenol A, and genistein all
induced small but significant reductions in
epithelial cell height. However, these
changes were transient, and where appropri-
ate time points were collected, no effects
were detected beyond day25 (Fig. 6).
Discussion
The efferent ducts are now recognized to be
an important site for both fluid resorption
and estrogen action within the male repro-
ductive tract (27). It is also becoming dear
that exposure to inappropriate levels of
estrogen can induce perturbations in nor-
mal fluid dynamics in this region and may
have consequences for male fertility.
Exposure to high levels of the synthetic
estrogen DES in neonatal life has previously
been shown to induce gross distension of
the rete testis and efferent ducts, as well as
reducing the level ofAQP-1 protein expres-
sion (20). Male mice that are homozygous
for a mutation in the gene encoding ERa
are infertile and show similar changes in
fluid dynamics postpubertally (27,28). In
view of these developments, we assessed
whether changes induced to the excurrent
duct system of the male might serve as a
biological indicator of inappropriate estro-
gen exposure duringdevelopment.
In the absence of specific biochemical
and molecular markers ofestrogen function
in the excurrent ducts, we assessed parame-
ters that we previously showed to change
after neonatal exposure to DES (20). We
assessed the level ofimmunoreactive AQP-
1 in the efferent duct epithelium and rete
testis, we observed efferent duct morpholo-
gy to assess any signs ofdistension, and we
measured efferent duct epithelial cell height
and testis weights from postnatal day 10
until adulthood in animals treated neona-
tally with estrogenic compounds. As a
point of reference, rats were treated with
various concentrations (10 pg, 1 pg, 0.1
pg/injection) of the potent synthetic estro-
gen DES. The effects of DES were com-
pared to those of ethinyl estradiol (10
pg/injection) and tamoxifen and to the
effects of weakly estrogenic compounds
(bisphenol A, octylphenol, parabens, and
the phytoestrogen genistein).
At day 18, neonatal exposure to DES
resulted in dose-dependent changes in all of
the parameters measured. The greatest effects
always occurred after the administration of 10
pg DES, and lesser effects were observed after
the administration of the two lower doses (1
and 0.1 pg), although the differences between
these two lowerdosesweresometimes margin-
al. At time points beyondday25, dose-depen-
dent effects ofDES were still evident on testis
weights, and epithelial cell height ofthe effer-
ent ducts still exhibited dose-dependent
changes at days 35 and 75 (testis weights
only). Our study failed to determine a no
observable effect level after neonatal adminis-
tration ofdecreasing doses of DES; further
studies using lower doses are in progress to
address this issue. The distension ofthe rete
testis and impairment of spermatogenesis
observed in this study after administering 10
pg DES (equivalent to -0.37 mg/kg/day) to
neonates are very similar to those published
recently after administration of 0.5 or 1 mg
estradiol benzoate/5 g bodyweight (100 or
200 mg/kg) onthedayofbirth (29).
The changes within the excurrent ducts
after neonatal DES treatment appear to be a
direct response to estrogen administration,
as animals treated neonatally with GnRHa
did not show any abnormalities except for a
transient reduction in efferent duct epithe-
lial cell height and a permanent reduction in
testis weight due to an approximate halving
in Sertoli cell numbers (21). Ethinyl estradi-
ol induced effects similar to those observed
20
E
=L0
._
20 eJ
15
10
5
Tre_nent Treatment
a Control
M GnRHa(10 mgkg)
M DES (10ppl M DES(1 gg
M DES (0.1 ig)
Ethinyl astradiol 110. g)
M Temoxifen (2mg/kg)
M Octylphenol(2mg)
M BisphenolAl0.5mg
mw P.rabmns(2mgfkgl
M Soy-free control
M Genistein(4mg/kg)
Treaent Treatment
Figure 6. Effect of neonatal treatmentwith a gonadotropin-releasing hormone antagonist(GnRHa) orvari-
ous estrogenic compounds on epithelial cell height in the efferent ducts at 18-75 days of age. The data
shown are means ± standard deviations for 3-20 animals/group. Genistein-treated animals were com-
pared with the soy-free control group on day 18.
*p<0.05;**p<0.01;ip<0.001 in comparison with the respective control group.
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after the administration of DES at the same
concentration of 10 pg/injection. All the
parameters measured showed a similar degree
of change, with the exception of rete testis
distension, which was not as severe as that
observed after treatment with the equivalent
dose of DES. The similarity in the effects
observed between ethinyl estradiol and DES
shows that these changes result from estro-
genic effects ofDES and not as the result of
some other toxic effect of this compound.
This conclusion is reinforced by the demon-
stration that neonatal exposure to tamoxifen
caused similar changes to the efferent ducts
(reduced immunoexpression ofAQP-1, dis-
tension of efferent ducts, and reduction in
epithelial cell height) at day 18 to those
induced by ethinyl estradiol and DES; thus,
these data show that this compound acts as
an agonist in the male reproductive tract as it
does at several other sites (e.g., bone). The
only minor difference observed between the
effect of 10 pg doses of DES and ethinyl
estradiol regarded the more severe distension
and overgrowth ofthe rete testis in the DES-
treated cohorts. The overgrowth of the rete
testis induced by these potent estrogens may
be related to the increased incidence of rete
testis adenocarcinoma (normally a rare neo-
plasm) that has been observed in both
humans and mice exposed to DES in utero
(30,31).
We also addressed the possibility that
weakly estrogenic compounds such as phy-
toestrogens or other xenoestrogens could
adversely affect development of the excur-
rent ducts. The results show that these
weak estrogens exert only minor effects on
the efferent ducts by marginally and tran-
siently reducing epithelial cell height dur-
ing puberty. No gross or prolonged
changes in the level of immunoexpression
ofAQP-1, efferent duct distension, or rete
testis morphology were detected after the
administration ofany ofthese compounds,
with the possible exception ofoctylphenol,
which may have caused marginal distension
of the efferent ducts at day 18. Due to the
transient nature of the effects observed
with these chemicals, it is probable that
prolonged exposure to very high levels ofa
weakly estrogenic compound would be
required for the persistence of any abnor-
mality in the parameters assessed.
The results in this paper show that
neonatal exposure to high levels of estrogen
causes deleterious changes in testis weight and
other end points. Although these effects per-
sisted long after the cessation of treatment,
most ofthe parameters measured, except for
testis weight and rete testis morphology, had
largely normalized by 75 days of age. Rete
testis morphology still showed signs ofdisten-
sion in both the ethinyl estradiol- and DES
(10 pg/injection)-treated animals by 75 days
of age, although this parameter is difficult to
assess in an objective or quantifiable way. It is
also difficult to compare rete testis morpholo-
gy between animals because cross-sections
from identical regions of the tissue must be
assessed and only gross changes can be detect-
ed easily. Any subtle effects that may have
been induced by xenoestrogens therefore
would not be detectable. Similarly, it is diffi-
cult to detect subtle changes in the level of
AQP-1 immunostaining that may have arisen
after treatment with weakly estrogenic com-
pounds. Therefore, the most useful parameters
measured were efferent duct epithelial cell
height and testis weight. Changes in testis
weight are very useful to gauge the overall
effects of treatment and, in adult animals,
testis weight has previously been shown to cor-
relate with daily sperm production (26).
Administration of other compounds, such as
GnRHa, produced a similar reduction in testis
weight to DES exposure (10 pg/injection),
demonstrating that this cannot be used as a
specific end point of inappropriate estrogen
exposure. The postnatal period is critical for
normal testis growth and alterations in Sertoli
cell numbers induced at this time point are
permanent, whereas other regions ofthe male
reproductive tract appear to be more plastic
and showed signs ofrecovery from estrogenic
effects. For example, at 75 days of age, rats
treated neonatally with DES (all doses)
showed significant reductions in testis weight,
whereas efferent duct epithelial cell height was
not significantly different from control values.
However, efferent duct epithelial cell height is
a useful, objective end point for assessing both
gross and subtle effects of estrogenic com-
pounds at earlier time points in development
and can also be used to monitor the duration
of these effects. Although the parameters
assessed in the present study together give a
strong indication ofeffects induced by estro-
genic chemicals on the reproductive tract, the
specificity ofthese effects remains to be estab-
lished: Can compounds that are not estrogenic
induce similar changes?
The present findings add to recent data
(20,27) which suggest that the excurrent
ducts and, in particular, the efferent ducts
are important physiological sites ofestrogen
action. Other data suggest that estrogens
play a central role in regulating fluid resorp-
tion from around the sperm as they travel
from the testis to the epididymis (32,33).
Of the fluid that enters the efferent ducts
from the testis, 96.2% is resorbed before
reaching the epididymis, along with most
inorganic electrolytes and proteins (32).
Many factors known to be involved in ion
and water movement (e.g., Na+-K+
ATPase, Na+-H+, and Cl-HCO3 exchang-
ers and Na+-K+-2C[3 symport) (34-36)
have been localized to the efferent ducts,
but as yet there is no information as to
which, if any, of these ion channels are
estrogen regulated. A good candidate mole-
cule is a member of the ABC transporter
family, which is involved in the pathology
that arises in individuals with inactivating
mutations in the cystic fibrosis (CF) gene.
The cystic fibrosis transmembrane regula-
tor (CFTR) is a cAMP-activated Cl- chan-
nel. It is well established that patients with
CF are often infertile due to degeneration
of the vas deferens, but some also suffer
from obstructive azoospermia due to the
deposition of thick mucous material in the
epididymal lumen (37,38). There is evi-
dence that a cAMP-activated C1- channel
exists in the epididymal epithelium
(39,40). Also, in situ hybridization studies
on human tissue have localized the mRNA
of this protein to the epididymis and vas
deferens, with the highest expression in the
head of the epididymis(41), raising the
likelihood ofits expression also in the effer-
ent ducts. CFTR may be a good candidate
for hormonal regulation because studies on
female rats have shown that estrogen up
regulates its expression in the uterine
epithelium (42,43). In addition, both CF
mutations and increased estradiol levels
have been found in otherwise healthy men
with reduced sperm quality (37,44).
It will be important in future studies to
establish which components ofthe fluid endo-
cytosis pathway in efferent ducts are estrogen
regulated because this may provide a more
direct and quantifiable end point of estrogen
exposure that can be applied to studies of the
effects of environmental and other estrogens
on development and function of the male
reproductive system.
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